Clinical trial
Neo-adjuvant Chemo and Immunotherapy with Durvalumab (MEDI4736) and Tremelimumab (MEDI1123) in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma: an Exploratory and Translational Study.
NCT06341764 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neo-adjuvant Chemo and Immunotherapy with Durvalumab (MEDI4736) and Tremelimumab (MEDI1123) in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma: an Exploratory and Translational Study.
- Lead sponsor
- National Cancer Institute, Naples
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 1, 2023
- Completion date
- September 30, 2025
- Enrollment
- 38 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.